Assessing the effectiveness and safety of zanubrutinib for marginal zone lymphoma patients in Italy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the efficacy and safety of zanubrutinib in patients with relapsed or refractory marginal zone lymphoma who have been treated under the Named Patient Program in Italy. It is a retrospective, multicenter study that aims to gather real-world data on the drug's performance in clinical practice. Data will be collected from the initiation of therapy until six months after treatment completion, providing insights into the drug's effectiveness and safety profile in this specific patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically confirmed diagnosis of relapsed/refractory marginal zone lymphoma
2. Patients who received at least one dose of zanubrutinib under the Named patient program (D.M. 7 Sep 2017), between January 2021 and October 2023 3) Age≥18 at start of zanubrutinib therapy. 4) Signature of written informed consent to study participation and personal data processing.

Exclusion Criteria:

1\) relapsed/refractory marginal zone lymphoma patients who received zanubrutinib in a clinical trial context.

Where it's running

• Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS
  Meldola, Forlì Cesena, Italy Recruiting
• AOU SS Antonio e Biagio e Cesare Arrigo
  Alessandria, Alessandria, Italy Not yet recruiting
• IRCCS-AOU di Bologna
  Bologna, Bologna, Italy Not yet recruiting
• P.O. Garibaldi-Nesima_UOC Ematologia
  Catania, Catania, Italy Not yet recruiting
• AO di Cosenza, P.O. "Annunziata" - UOC di Ematologia
  Cosenza, Cosenza, Italy Not yet recruiting
• AOU di Ferrara_ UO di Ematologia - Dipartimento di Oncologia e Medicine Specialistiche
  Ferrara, Ferrara, Italy Not yet recruiting

Study contacts

• Principal investigator: Pier Luigi Zinzani, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
• Study coordinator: Pier Luigi Zinzani, MD
• Email: pierluigi.zinzani@unibo.it
• Phone: +39 0512143680

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Zanubrutinib plus Lenalidomide for frail elderly with newly diagnosed PCNSL

  This study tests whether a combination of zanubrutinib and lenalidomide can help frail elderly patients with newly diagnosed primary CNS lymphoma.

  Recruiting Phase 2 Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07839247

• Venetoclax plus Zanubrutinib for CLL/SLL in frontline or previously treated patients

  This phase II trial tests if venetoclax plus zanubrutinib can safely and effectively treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, including those who are newly diagnosed and those who have had prior therapy.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07734038

• MRD-guided Zanubrutinib + Sonrotoclax in new high-risk CLL/SLL

  This trial tests a time-limited, MRD-guided combination therapy with zanubrutinib and sonrotoclax for adults up to 75 with previously untreated high-risk CLL/SLL.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07671378

• Polatuzumab vedotin with Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in untreated DLBCL (MCD/BN2/N1)

  This study tests a targeted combination therapy to see if it can treat previously untreated DLBCL with specific molecular subtypes.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07608978

• Pola-ZR-Glo for older patients with large B‑cell lymphoma

  This trial will try combining polatuzumab vedotin, zanubrutinib, lenalidomide, and glofitamab as first-line treatment for people aged 70 and older with newly diagnosed large B‑cell lymphoma who are unfit for standard chemo or decline immunochemotherapy.

  Recruiting Phase 2 Ruijin Hospital · Shanghai · NCT07514169

• Orelabrutinib plus rituximab with optional lenalidomide for untreated marginal zone lymphoma using a response-adapted plan

  This will test whether giving orelabrutinib with rituximab, and adding lenalidomide for those who don't fully respond, helps people with newly diagnosed marginal zone lymphoma achieve complete remissions.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07448324

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.